US ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

US ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Executive Summary

A CAGR of 5.5% is anticipated for the US ADHD (Attention Deficit Hyperactivity Disorder) treatment market from 2022 to 2030, growing from $12.4 Bn in 2022 to $19.1 Bn in 2030.

Due to the rising incidence of ADHD and the availability of efficient treatment alternatives, the US therapeutic market for ADHD (Attention Deficit Hyperactivity Disorder) is expanding quickly.

Treatment options for people with ADHD are referred to as ADHD (Attention Deficit Hyperactivity Disorder) Therapy. Inattention, hyperactivity, and impulsivity are some of the symptoms of ADHD, a neurodevelopmental condition. While it is frequently identified in children, ADHD can last until adulthood. Although the precise aetiology of ADHD is unknown, a confluence of genetic, environmental, and neurological factors is thought to be responsible.

Medication, behavioural therapy, and lifestyle changes are just a few of the therapies for ADHD that are available. Stimulants like methylphenidate and amphetamine are the most often recommended treatments for ADHD because they raise dopamine and norepinephrine levels in the brain. For people who do not respond well to stimulants or who have negative effects from them, non-stimulant medicines such as atomoxetine and guanfacine may be utilised.

For those with ADHD, particularly youngsters, behavioural treatment might be helpful. Working with a therapist or counsellor to develop behavioural methods and coping mechanisms that can help control ADHD symptoms is known as behavioural therapy. For those with ADHD, making lifestyle changes like exercising and adopting a nutritious diet may be helpful.

Market Dynamics

Market Growth Drivers

Due to the lack of a cure for this disorder, the prevalence of ADHD is increasing at a faster rate, which drives the US market for therapeutics for the condition. Additionally, the market for ADHD therapeutics is primarily driven by the negative effects of unstable lifestyles and food additives on children, which is increasing the prevalence of ADHD in people between the ages of 4 to 17. Additionally, it is predicted that in the near future, the US market for ADHD will experience revenue growth due to rising awareness of the syndrome among doctors and patients as well as opinion-based treatment options caused by the absence of routine diagnostic tests.

Market Restraints

The development of the US market for ADHD therapeutics is being constrained by the high cost of ADHD medications, poor reimbursement policies, and side effects associated with ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes). The adverse effects of ADHD medications also negatively impact patients' quality of life and restrain the market's revenue growth over the given forecast period. Aside from these issues, medications for attention deficit hyperactivity disorder are linked to medical conditions like kidney disease, coronary artery disease, and seizures.

Competitive Landscape

Key Players

• Shire (currently part of Takeda Pharmaceutical Company) (now part of Takeda Pharmaceutical Company)
• Pfizer, Inc.
• Incorporated by Novartis
• Smith & Johnson
• Firm named Eli Lilly
• PLC GlaxoSmithKline
• Pharmaceutical company Teva Industries Ltd.
• Impax Laboratories, LLC, Mylan N.V.
• Pharmaceutical company Mallinckrodt

These businesses also produce additional therapeutic goods including behavioural treatment programmes in addition to a variety of ADHD medicines, including stimulant and non-stimulant drugs. These businesses dominate the market and are responsible for generating both innovation and competition. The development of novel ADHD therapies and technology by several smaller businesses and startups may potentially have an impact on the market in the future.

Healthcare Policies and Regulatory Landscape

The US Food and Drug Administration (FDA) regulates the US ADHD treatment market, which is also subject to a variety of healthcare laws and regulations. Following are some significant laws and rules that affect the market:

1. FDA Approval: Before being marketed and sold in the US, all ADHD drugs must have FDA approval. The FDA evaluates evidence from clinical trials and other sources to assess the effectiveness and safety of each drug.
2. The Drug Enforcement Agency (DEA) has classed certain ADHD drugs as Schedule II prohibited narcotics due to their propensity for misuse and dependency. The prescribing and distribution of certain pharmaceuticals are subject to extra rules as a result of this categorization.
3. Medicaid Coverage: ADHD medicines and other therapeutic interventions are covered by Medicaid for those who qualify, which has a big influence on the market demand for these items
4. Healthcare insurers are required to cover mental health problems, including ADHD, under the requirements of the Affordable Care Act (ACA). For people with ADHD, this has boosted access to treatment alternatives.
5. Guidelines for Diagnosis and Treatment: For the diagnosis and management of ADHD, the American Academy of Pediatrics and other medical associations have issued recommendations. These recommendations for best practices might have an effect on how ADHD drugs are prescribed and used.
6. Adverse Event Reporting: The FDA requires ADHD drug manufacturers to notify it of any adverse events or side effects related to their medicines. This enables continuous monitoring and evaluation of the risks and advantages of certain treatments, helping to assure their safety.

Overall, these laws and rules are crucial in establishing the US ADHD therapeutic market, guaranteeing the effectiveness and safety of ADHD drugs and other therapies, and facilitating access to healthcare for people with ADHD.